Podcast
FDA Approval Insights: Pirtobrutinib in MCL
Author(s):
In Partnership With:
Dr Leslie discusses the FDA approval of pirtobrutinib in patients with MCL previously treated with a BTK inhibitor, key efficacy and safety findings from the BRUIN trial, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with Lori A. Leslie, MD, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, about the FDA approval of pirtobrutinib (Jaypirca) in mantle cell lymphoma (MCL).
On January 27, 2023, the FDA approved pirtobrutinib, a noncovalent reversible BTK inhibitor, in patients with MCL previously treated with a BTK inhibitor. The regulatory decision was based on findings from the phase 1/2 BRUIN trial (NCT03740529), in which the agent led to an objective response rate of 51% (95% CI, 41%-61%) in BTK-pretreated patients and 82% (95% CI, 48%-98%) in BTK-naïve patients.
In our exclusive interview, Dr Leslie discussed the significance of this approval, key efficacy and safety findings from BRUIN, and potential treatment sequencing strategies in patients with resistance to covalent BTK inhibitors.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
